Ann Rheum Dis: Phase II Trial of Kanamono Anti-Still Disease in Adults

Inhibition interleukin (IL)-1 is a promising treatment option for adult Still disease (AOSD)explored the efficacy and safety of carnamono in patients with a stressed AOSD in active joints through a multicenter, double-blind, randomized, and placebo-controlled trialpatients with AOSD whoactive joints (both the count of the pain and swelling joints) received kanamono (4 mg/kg, up to 300 mg of subcutaneous injections every 4 weeks) or placeboThe primary endpoint was the proportion of patients with clinically related decline in disease activity as determined by changes in disease activity scores at the 12th week (DAS22were more active in the group, with the average DAS28 (ESR) in the Kanamono group of patients being 5.4 and the placebo group 5.3In the intent-treatment analysis, 12 patients in the Kanada group (67%) and 7 patients in the placebo group (41%) met the primary outcome criteria (p-0.18)In a programmed analysis, the American Society of Rheumatology (ACR) in the Canaclan group (ACR) was 30% (61% vs 20%, p.033), ACR 50% (50% vs 6.7%, p.009) and ACR 70% (28% vsvs.) compared to the placebo group0%, p-0.049) the response rate is significantly higherTwo patients in the Kanamono-anti group experienced severe adverse eventsalthough the study ended prematurely and did not reach the main endpoint, the use of Kanamono therapy could improve several prognostic indicators of AOSDThe overall security findings are consistent with the known characteristics of CananoTherefore, the data for this study support the use of Kanamono anti-inhibition IL-1 in AOSD